Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Payables: 2017-2024

Historic Payables for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $21.5 million.

  • Crinetics Pharmaceuticals' Payables rose 84.28% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.8 million, marking a year-over-year increase of 32.60%. This contributed to the annual value of $21.5 million for FY2024, which is 7.45% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Payables of $21.5 million as of FY2024, which was down 7.45% from $23.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Payables registered a high of $23.2 million during FY2023, and its lowest value of $5.6 million during FY2020.
  • Moreover, its 3-year median value for Payables was $21.5 million (2024), whereas its average is $20.0 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Payables surged by 81.28% in 2022, and later fell by 7.45% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Payables (Yearly) stood at $5.6 million in 2020, then soared by 51.54% to $8.5 million in 2021, then skyrocketed by 81.28% to $15.4 million in 2022, then spiked by 51.10% to $23.2 million in 2023, then decreased by 7.45% to $21.5 million in 2024.